Last updated on November 2019

Safety Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Von Gierke's disease
  • Age: Between 1 - 18 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Glycogenosis type 1b confirmed by biochemical analyzes and / or genetic analysis. These patients with Glycogenosis must have had a liver transplant
  • Alternatively, G6PC3 deficiency confirmed by genetic analysis
  • Age 1 to 18 years old female or male
  • Informed consent signed by the recipient and / or parents / assigns.
  • Information and agreement of the referring medical team.
  • A Negative Blood Pregnancy Test at the time of screening and a negative urinary pregnancy test at Day 1 of the protocol are required for female with child bearing potential.
  • Sexually active patients should use an effective method of contraception throughout the duration of the study and up to 7 days after the last dose of Empaglifozine. (The combination of a hormonal method and a barrier method; Two barrier methods, the male condom being one of these two methods;Use intrauterine device or tubal ligation;-A total sex abstinence.)

Exclusion Criteria:

  • Presence of advanced fibrosis (Metavir F4) or cirrhosis.
  • Impossibility of long-term and / or non-compliance monitoring.
  • Other medical problems which, in the opinion of the physicians in charge of the patient, would constitute a contraindication to the procedure.
  • Sexually active patients who do not consent to use effective contraception during the study.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.